2019年国际泌尿病理学会(ISUP)前列腺癌分级共识会议
该文总结2019年9月在法国尼斯召开的ISUP前列腺癌分级共识会议。共识涉及Gleason 4/5模式及次要/三级模式的报告、浸润性筛状癌的报告、导管内癌纳入分级、系统与MRI靶向活检的单独或汇总分级,并讨论人工智能与未来研究方向。
要点
- 共识同意报告浸润性筛状癌的存在。
- 共识同意将导管内癌纳入分级。
- 讨论系统与MRI靶向活检的单独或汇总分级。
核心结论
- 新数据和临床实践变化要求更新前列腺癌病理分级指南,会议就多个分级报告问题达成共识。
研究设计与样本
- ISUP共识会议于2019年9月在法国尼斯召开,总结会议内容。
主要发现
- 共识议题包括Gleason 4和5模式数量及次要/三级模式的报告方法。
- 会议同意报告浸润性筛状癌的存在。
- 会议同意将导管内癌纳入分级。
- 会议讨论了系统活检与多参数MRI靶向活检的单独或汇总分级。
- 会议还讨论了人工智能在前列腺癌分级中的进展及未来研究前景。
临床怎么用
- 病理报告应报告浸润性筛状癌的存在。
- 前列腺癌分级应将导管内癌纳入。
- 系统与MRI靶向活检可采用单独或汇总分级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Five years after the last prostatic carcinoma grading consensus conference of the International Society of Urological Pathology (ISUP), accrual of new data and modification of clinical practice require an update of current pathologic grading guidelines. This manuscript summarizes the proceedings of the ISUP consensus meeting for grading of prostatic carcinoma held in September 2019, in Nice, France. Topics brought to consensus included the following: (1) approaches to reporting of Gleason patterns 4 and 5 quantities, and minor/tertiary patterns, (2) an agreement to report the presence of invasive cribriform carcinoma, (3) an agreement to incorporate intraductal carcinoma into grading, and (4) individual versus aggregate grading of systematic and multiparametric magnetic resonance imaging-targeted biopsies. Finally, developments in the field of artificial intelligence in the grading of prostatic carcinoma and future research perspectives were discussed.
引用
- van Leenders GJLH, van der Kwast TH, Grignon DJ, et al. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. Am J Surg Pathol. 2020. PMID: 32459716. doi:10.1097/PAS.0000000000001497
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。